Merck has launched a service, Biosimilars Clarified, which is intended to explain the purpose, function, and benefits of biosimilars to the health care community, according to a recent press release.1

The service offers users a chance to “gain clarity” about biosimilars, and is aimed at 3 audiences: health care professionals, payers, and patients/caregivers. The questions from which users choose range from basic scientific information to statements about Merck’s “commitment to biosimilars.”

The Biosimilars Clarified webpage states that there is much “complexity and confusion about biosimilars: what they are, how they are made, and why they should matter to you and the health care system. Clear, concise answers and straightforward information can help you feel more confident about biosimilars.”2

RELATED: Biosimilar Equivalent to Pegfilgrastim for Chemo-induced Neutropenia Prophylaxis

It is unclear, however, how this service offers more helpful information than the U.S. Food and Drug Administration’s page about biosimilars.

References

  1. Merck launches biosimilars clarified, a new online educational resource about biosimilar medicines for patients and the healthcare community [press release]. Merck website. http://www.mercknewsroom.com/news-release/corporate-news/merck-launches-biosimilars-clarified-new-online-educational-resource-abo. Updated October 14, 2016. Accessed November 1, 2016.
  2. Biosimilars Clarified. Merck website. https://www.merckclarifiesbiosimilars.com/. Accessed November 1, 2016.